‘Product hopping’ under fire in Senate bill

When Allergan withdrew Alzheimer's disease drug Namenda memantine from the market so physicians would prescribe a reformulated once-daily version with a longer patent life, the company was engaging in an anticompetitive practice, according to Sen. John Cornyn (R-Texas). Legislation Cornyn sponsored would subject such practices to FTC scrutiny and possible litigation.